🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

RecruitingNAAges 19 Years - anyFemaleSeoul National University Hospital
NCT06977594 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer. The main questions it aims to answer are: \- Does immune tolerance induction during the first three cycles of chemotherapy reduce the incidence of hypersensitivity reactions in the remaining cycles? Participants will: * Undergo immune tolerance induction or standard treatment during the first three cycles of chemotherapy as randomized, after which all participants will continue the remaining cycles with standard treatment. * Receive a reduced dose of dexamethasone premedication if assigned to the experimental group, depending on the specific protocol of each clinical trial.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients receiving paclitaxel and carboplatin chemotherapy for gynecologic malignancies. * Patients with no prior history of hypersensitivity reactions to paclitaxel or carboplatin. * Patients who are able to read and voluntarily provide written informed consent. * Aged 19 years or older. Exclusion Criteria: * Patients who do not wish to participate in this study voluntarily. * Patients who, in the opinion of the investigator, are unsuitable for participation in this clinical trial.
💊

What it tests

  • Proactive immune tolerance induction
  • Standard Treatment
  • Paclitaxel and carboplatin
  • Standard premedication (20 mg)
  • Reduced premedication (10 mg)
📍

Where

1 site
Seoul National University Hospital
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy